Bromine Compounds Limited

Other

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hadasit Medical Research Services and Development Ltd.

Novotyr Therapeutics Ltd.

Iris Ben-David

Alexander Levitzki

Ben-Zion Magnes

Eyal Yosef Mishani

Yulia Rozen

Hadas Reuveni

Eli Lancry

Ran Elazari

Ronny Costi

Igor Kompaniets

Revital Sasson

Giuseppina Ortu

Gluseppina Ortu

Neta Cohen

Gershon Miaskovski

Lilach Steiner

Avi Weissberg

The invention relates to an electrolyte solution suitable for use in a zinc-bromine battery, comprising zinc bromide and a mixture of at least two complexing agents selected from the group consisting of 1-R-2-methyl pyridinium bromide and 1-R-3-methyl pyridinium bromide salts, wherein each of Rand Ris independently an alkyl group having not less than five carbon atoms.

Additives for a flow battery

The invention relates to a method of operating a zinc-bromine battery, especially at a high temperature, comprising adding 1-n-butyl-2-methyl-pyridinium bromide to the electrolyte of said battery, and charging or discharging said cell. Also provided is the use of 1-n-butyl-2-methyl-pyridinium bromide as an additive in a zinc-bromine battery operating at a temperature above 30&#xb0; C., and an aqueous concentrate with high content of 1-n-butyl-2-methyl-pyridinium bromide.

Additive for a flow battery

A process for preparing an aqueous solution of N-ethyl-2-methylpyridinium bromide (2-MEPy), comprising reacting 2-picoline and ethyl bromide in a pressure reactor at a temperature above the melting point of the reaction mixture, combining the reaction product with water, wherein said reaction product consists essentially of 2-MEPy in a liquid form, and recovering an aqueous solution of 2-MEPy.

Processes for preparing N-ethyl-2-methylpyridinium bromide and N-ethyl-3-methylpyridinium bromide

The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Protein kinase modulators and therapeutic uses thereof

Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy

Growing community of inventors

Ashdod, Israel

Iris Ben-David